Fulgent Genetics Inc Stock
€19.40
Your prediction
Fulgent Genetics Inc Stock
Pros and Cons of Fulgent Genetics Inc in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.A preliminary view of Fulgent Genetics' financials presents an interesting picture. A company in the Healthcare Equipment & Supplies industry, it shows a mixture of strengths and areas of concern.
Starting with the fortified aspects, Fulgent Genetics has demonstrated significant revenue growth year on year, rising from $421.712 million in 2020 to $992.584 million in 2021. This surge in revenue reflects the ability of the firm to maximize its business operations and gain greater market share. The balance sheet also suggests a solid financial foundation with a notable increase in total assets, from $700.461 million in 2020 to $1.388 billion by 2022.
The company has also managed to maintain a good control over its total liabilities, with minimal ups and downs, reflecting astute financial management. The ratio of total liabilities to total assets has dwindled over the analyzed period, hinting towards increasing financial stability. Moreover, an impressive increment in retained earnings from $150.881 million in 2020 to $801 million in 2022 offers a promising outlook for Fulgent Genetics.